5,000 to 10,000 Compounds Yield 1 New Drug to Market | Step | Number of Compounds | Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | Discovery – identifying and screening | 5,000—10,000 | | | | | | | | | | | | | | | | | Preclinical Testing – in laboratory and animal studies | 250 | | | | | | | | | | | | | | | | | Phase I – Clinical Testing. Safety and dosage evaluated on 20-100 healthy human volunteers | 5 | | | | | | | | | | | | | | | | | Phase II – Clinical Testing. Efficacy and side effects tested on 100-500 patient volunteers | 1 | | | | | | | | | | | | | | | | | Phase III – Clinical Testing. Effectiveness and reactions to long-term use tested on 1,000 to 5,000 patient volunteers | 1 | | | | | | | | | | | | | | | | | FDA Review and Approval | 1 | | | | | | | | | | | | | | | | |
|